Drug intelligence / Profile preview

LAD603

Development stage: Phase 2
Lead developer: Almirall
Modality: Small Molecules
Administration: Subcutaneous

Overview

LAD603 is an investigational drug being developed by Almirall. It is currently in early-stage clinical development as a subcutaneous injection formulation. The primary focus of ongoing studies is to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and pharmacodynamics (PD) of single and multiple ascending doses in healthy adult participants. As of now, the specific mechanism of action and therapeutic indication for LAD603 have not been publicly disclosed. The drug has reached Phase 1 clinical trials but no efficacy or target data are available[1][3][4][5][7].

Beyond the preview

Go deeper on LAD603.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LAD603.

Explore the full profile